ArticleTherapeutic advances in medical oncology2024

Comparison of neoadjuvant chemotherapy response and prognosis among pegylated liposomal doxorubicin, epirubicin and pirarubicin in HR ⩽ 10%/HER2-negative breast cancer: an exploratory real-world multicentre cohort study.

Yue Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.